Literature DB >> 20592068

Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes.

Lubbertus C F Mulder1, Marcel Ooms, Susan Majdak, Jordan Smedresman, Caitlin Linscheid, Ariana Harari, Andrea Kunz, Viviana Simon.   

Abstract

Multiple APOBEC3 proteins are expressed in HIV-1 target cells, but their individual contributions to viral suppression when expressed at endogenous levels remain largely unknown. We used an HIV NL4-3 mutant that selectively counteracts APOBEC3G (A3G) but not APOBEC3F (A3F) to dissect the relative contribution of A3F to the inhibition of HIV-1 replication in primary human lymphocytes (peripheral blood mononuclear cells [PBMCs]). This HIV Vif mutant replicated similarly to wild-type virus in PBMCs, suggesting that the effect of A3F on HIV restriction in these cells is limited. The different A3F variants found in PMBC donors displayed either comparable activity or less activity than wild-type A3F. Lastly, the endogenous A3F mRNA and protein expression levels in PBMCs were considerably lower than those of A3G. Our results suggest that A3F neutralization is dispensable for HIV-1 replication in primary human T-lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20592068      PMCID: PMC2937628          DOI: 10.1128/JVI.02630-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Authors:  Craig Pace; Jean Keller; David Nolan; Ian James; Silvana Gaudieri; Corey Moore; Simon Mallal
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.

Authors:  Brian P Doehle; Alexandra Schäfer; Bryan R Cullen
Journal:  Virology       Date:  2005-09-01       Impact factor: 3.616

3.  Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.

Authors:  M Janini; M Rogers; D R Birx; F E McCutchan
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.

Authors:  Louis Alexander; Mary Janette Aquino-DeJesus; Michael Chan; Warren A Andiman
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.

Authors:  Eric W Refsland; Mark D Stenglein; Keisuke Shindo; John S Albin; William L Brown; Reuben S Harris
Journal:  Nucleic Acids Res       Date:  2010-03-22       Impact factor: 16.971

6.  Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets.

Authors:  Fransje A Koning; Edmund N C Newman; Eun-Young Kim; Kevin J Kunstman; Steven M Wolinsky; Michael H Malim
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

7.  Cytidine deamination induced HIV-1 drug resistance.

Authors:  Lubbertus C F Mulder; Ariana Harari; Viviana Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

8.  Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification.

Authors:  Viviana Simon; Veronique Zennou; Deya Murray; Yaoxing Huang; David D Ho; Paul D Bieniasz
Journal:  PLoS Pathog       Date:  2005-07-22       Impact factor: 6.823

9.  Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.

Authors:  Gang Peng; Ke Jian Lei; Wenwen Jin; Teresa Greenwell-Wild; Sharon M Wahl
Journal:  J Exp Med       Date:  2006-01-17       Impact factor: 14.307

Review 10.  HIV-1 Vif, APOBEC, and intrinsic immunity.

Authors:  Ritu Goila-Gaur; Klaus Strebel
Journal:  Retrovirology       Date:  2008-06-24       Impact factor: 4.602

View more
  29 in total

1.  The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Authors:  Mawuena Binka; Marcel Ooms; Myeika Steward; Viviana Simon
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.

Authors:  Judd F Hultquist; Joy A Lengyel; Eric W Refsland; Rebecca S LaRue; Lela Lackey; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 3.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

4.  Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.

Authors:  John S Albin; William L Brown; Reuben S Harris
Journal:  Virology       Date:  2013-12-20       Impact factor: 3.616

5.  Authentication Analysis of MT-4 Cells Distributed by the National Institutes of Health AIDS Reagent Program.

Authors:  Melissa V Fernandez; Krista A Delviks-Frankenberry; David A Scheiblin; Christine Happel; Vinay K Pathak; Eric O Freed
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

6.  Long-term passage of Vif-null HIV-1 in CD4+ T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance.

Authors:  Eri Miyagi; Sandra Kao; Miyoshi Fumitaka; Alicia Buckler-White; Ron Plishka; Klaus Strebel
Journal:  Virology       Date:  2017-01-25       Impact factor: 3.616

Review 7.  Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature.

Authors:  Jean-François Gélinas; Deborah R Gill; Stephen C Hyde
Journal:  Microbiol Mol Biol Rev       Date:  2018-01-10       Impact factor: 11.056

8.  Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.

Authors:  Yukie Iwabu; Masanobu Kinomoto; Masashi Tatsumi; Hideaki Fujita; Mari Shimura; Yoshitaka Tanaka; Yukihito Ishizaka; David Nolan; Simon Mallal; Tetsutaro Sata; Kenzo Tokunaga
Journal:  J Biol Chem       Date:  2010-09-10       Impact factor: 5.157

9.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.

Authors:  Michael S Harper; Bradley S Barrett; Diana S Smith; Sam X Li; Kathrin Gibbert; Ulf Dittmer; Kim J Hasenkrug; Mario L Santiago
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.